Novo Nordisk's CEO is not worried about blockbuster semaglutide drugs being added to Medicare drug pricing negotiations this ...

Novo Nordisk NVO is scheduled to report fourth-quarter 2024 results on Feb. 5, 2025, before the opening bell. The Zacks ...

List prices exceed $1,000 per month and spotty insurance ... Novo Nordisk sells the drug semaglutide under the brands Ozempic for diabetes and Wegovy for weight loss. The company's older weight ...

Coverage of obesity drugs in health plans and the rapid adoption of artificial intelligence are two areas of change that health plans will face during the coming year. A panel of Avalere experts ...

Ozempic/Wegovy is the first drug on HHS's 2025 list of Medicare price negotiations. As the leaders of the pharmaceutical industry boarded their planes to come home from the JP Morgan Healthcare ...

We came across a bullish thesis on Novo Nordisk A/S (NVO) on Long-Term Pick’s Substack by Dan. In this article, we will summarize the bulls’ thesis on NVO.

Novo Nordisk A/S NVO reported fourth-quarter 2024 earnings of 91 cents per American Depositary Receipt (ADR), which beat the ...

Why would Trump be OK with forcing Americans to pay more than the rest of the world for their drugs? The answer is simple: ...

There is no record of Denmark announcing the tariff on Ozempic exports. The social media user who first shared the claim ...

Medicare will soon negotiate prices for 15 more drugs as part of an effort to reduce costs for older adults and people with disabilities.